Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12824606 | 0.94 | ALDH1A1 (0.71) | ALDH1A1TDP1MAPTGAAKDM4E | |
| SCHEMBL12824361 | 0.84 | ALDH1A1 (0.96) | ALDH1A1TDP1MAPTGAAKDM4E | |
| SCHEMBL13711958 | 0.82 | ALDH1A1 (1.00) | ALDH1A1TDP1MAPTGAAKDM4E | |
| SCHEMBL12515889 | 0.82 | ALDH1A1 (1.00) | ALDH1A1TDP1MAPTGAAKDM4E | |
| SCHEMBL12824322 | 0.81 | ALDH1A1 (0.67) | ALDH1A1TDP1MAPTGAAKDM4E | |
| SCHEMBL12824499 | 0.81 | ALDH1A1 (0.72) | ALDH1A1TDP1MAPTGAAKDM4E | |
| SCHEMBL7231518 | 0.79 | ALDH1A1 (0.70) | ALDH1A1TDP1MAPTKDM4EKCNJ1 | |
| SCHEMBL1554083 | 0.79 | TDP1 (1.00) | ALDH1A1TDP1MAPTKCNJ1RAB9A | |
| SCHEMBL2750222 | 0.77 | SMN1; SMN2 (0.49) | ALDH1A1MAPTGAAKDM4ESMN1; SMN2 | |
| SCHEMBL20771270 | 0.76 | TDP1 (0.65) | ALDH1A1TDP1MAPTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535386-B | Cyanoethylene sulfonyl anilide compound and preparation method and medical application thereof | 西南大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-108383858-B | Derivatives of imidazothiadiazoles and imidazopyrazines for the treatment of platelet aggregation | 百时美施贵宝公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-116535386-A | Cyanoethylene sulfonyl anilide compound and preparation method and medical application thereof | 西南大学 | 2023-08-04 | — | — | CN | disclosed |
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | INVENTIVA (FR) | 2020-04-16 | — | — | US | disclosed |
| EP-3606921-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | Inventiva (FR) | 2020-02-12 | — | — | EP | disclosed |
| CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 伊文蒂瓦公司 | 2020-01-17 | — | — | CN | disclosed |
| EP-1470102-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
| EP-0727463-B1 | Triazolopyridine dyes and intermediate products therefor | BASF AG (DE) | 2000-05-03 | — | — | EP | disclosed |
| US-5700757-A | THERMAL TRANSFER OF DYES FROM SUPPORT TO A PLASTIC COATED PAPER BY DIFFUSION OR SUBLIMATION; DYEING OR PRINTING SYNTHETIC FABRICS | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-23 | — | — | US | disclosed |
| EP-0727463-A2 | Triazolopyridine dyes and intermediate products therefor | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-21 | — | — | EP | disclosed |
| EP-0416434-B1 | Triazole pyridine dyes and a thermal transfer process of methine dyes | BASF AG (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5147845-A | Printing | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-15 | — | — | US | disclosed |
| US-5079365-A | TRIAZOLOPYRIDINE DYES AND THERMAL TRANSFER OF METHINE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1992-01-07 | — | — | US | disclosed |
| EP-0416434-A2 | Triazole pyridine dyes and a thermal transfer process of methine dyes | BASF Aktiengesellschaft (DE) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | ALDH1A1 2424/4885TDP1 688/4885MAPT 1886/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | ALDH1A1 1723/4885TDP1 2688/4885MAPT 4443/4885 |
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | YAP1, TEAD2, TEAD1 | ALDH1A1 3397/4885TDP1 2138/4885MAPT 1811/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885TDP1 1447/4885MAPT 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.